April 14, 2021
FDA pauses vaccination with J&J vaccine after six cases of blood clot
U.S. CDC and FDA called for a pause in the J&J’s vaccine use following the emergence of a rare blood clotting disorder in six recipients.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: J&J
March 29, 2019
Global Preventive Vaccines Market Growth, Trends and Forecasts (2019-2024): AstraZeneca, Emergent BioSolutions, Daiichi Sankyo Co, GlaxoSmithKline, and Johnson & Johnson are Dominating – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
March 27, 2019
Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
First DARZALEX combination regimen being pursued as frontline treatment option for transplant eligible patients with multiple myeloma BEERSE, Belgium–(BUSINESS WIRE)–The…
December 4, 2017
Idorsia welcomes $230 million milestone for Janssen’s agreement opt-in decision
Idorsia said Monday Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has exercised its option to enter…
June 28, 2017
Janssen’s Xarelto designated for priority review
Janssen Research & Development, said Wednesday the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban).
June 21, 2017
U.S. Supreme Court ruling threatens masive talc litigation against J&J
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.
May 16, 2017
New York county sues Purdue, J&J over opioid marketing
A county in New York state has sued Purdue Pharma LP, Johnson & Johnson <JNJ.N> and other drugmakers, accusing them of engaging in fraudulent marketing that played down the risks of prescription opioid painkillers, leading to a drug epidemic.
March 31, 2017
J&J expect to close successful $30 billion Actelion tender offer in second quarter
Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.
December 22, 2016
Biocartis submits 510(k) to FDA, expands European hospitals deal with Amgen
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
December 14, 2016
J&J shareholding in Biocartis decreases
Johnson&Johnson has decreased its shareholding in Biocartis, the Belgian drugmaker said on Wednesday. In a disclosure of a transparency notification,…